Loading...
•
Sep 30, 2021
Agenus Q3 2021 Earnings Report
Agenus reported financial results for the third quarter of 2021 and provided a corporate update.
Key Takeaways
Agenus reported a net income of $177 million, or $0.76 per share basic and $0.72 per share diluted, and ended the quarter with $262 million in cash and short-term investments. The company also highlighted clinical responses achieved with AGEN1181, the launch of MiNK Therapeutics' IPO, and the launch of its adjuvant business, SaponiQx.
AGEN1181 shows clinical benefit in 9 cold and treatment-resistant tumor types.
MiNK Therapeutics launched an IPO and is trading on NASDAQ.
SaponiQx launch to accelerate development of proven and novel adjuvants.
First patients dosed in multiple collaborator programs.